Zhouguang Hui, MD |National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Shugeng Gao, MD; Yuchen Jiao, PhD; Kuo Men, PhD; Jianming Ying, MD; Yu Men, MD; Xu Yang, MD
Competition Sponsor: Chinese Academy of Medical Sciences
Awardee Year: 2022
BACKGROUND and AIMS: The populations who can benefit from postoperative radiotherapy (PORT) for non-small cell lung cancer (NSCLC) is unknown. This study aims at predicting the efficacy of PORT and prognosis for elderly patients with N2-NSCLC based on minimal residual disease (MRD) and artificial intelligence (AI).
Study Design: This is an ambispective cohort study based on databases and biobanks of the phase III randomized controlled study and the real-world study. MRD combined with AI will be utilized to build and validate the predictive and prognostic models.
Expected Outcomes: ① Establishing an efficient MRD detection methodology; ② building and validating the predictive and prognostic models; ③ communicating in 1-2 academic conferences; ④ Training one postgraduate.
Fundamentals: ① The applicant is a National Talent Program winner, and has conducted long-term, extensive and in-depth explorations on the issue of PORT in N2 NSCLC. The series of studies represented by the prospective phase III clinical trial PORT-C are of international leading level; ② The backbones of the project have conducted extensive and in-depth research in tumor molecular biology, artificial intelligence and tumor pathology, undertaken a number of relevant national projects, and been selected into a number of national talent programs; ③ The research group has established databases and biobanks from thousands of N2-NSCLC, which meets the research needs; ④ The National Cancer Center is a cancer center integrating medicine, teaching, research, learning and prevention of cancer. There are more than 200 cases of N2-NSCLC receiving radical resection per year.
To learn more about this proposal, email email@example.com.